HIGH DOSE CHEMOTHERAPY AND COMBINATION ANTI-HIV THERAPY FOR HIV ASSOCIATED HO

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究的目的是确定是否可以从正在接受联合抗HIV治疗的HIV感染患者身上收集外周血祖细胞(可以成为血细胞的未成熟细胞)。这些细胞将在非霍奇金淋巴瘤(NHL)或霍奇金病(HD)的大剂量化疗后回馈给研究参与者。其他目的是评估这种治疗的副作用，并估计无病生存率和总存活率。HIV相关NHL/HD患者接受常规化疗和/或放射治疗后预后很差。虽然可以缓解(没有可检测到的淋巴瘤)，但缓解的时间通常很短。最近的研究表明，患有NHL/HD但没有感染艾滋病毒的人，如果接受大剂量化疗以努力摧毁任何剩余的NHL/HD，可以实现长期缓解。然而，这种强化治疗也会破坏正常的骨髓细胞。为了帮助减少这一问题，患者的外周血祖细胞(PBPC)可以在化疗过程中采集，在强化治疗结束后通过静脉(通过静脉)返回受试者。这一过程被称为自体PBPC移植。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to determine whether peripheral blood progenitor cells (immature cells that can become blood cells) can be collected from patients with HIV infection who are being treated with combination anti-HIV therapy. These cells will be given back to research participants after high dose chemotherapy for non-Hodgkin's lymphoma (NHL) or Hodgkin's Disease (HD). Additional purposes are to evaluate the side effects of this treatment and estimate the disease-free and overall survival. The prognosis of patients with HIV-related NHL/HD is very poor with conventional chemotherapy and/or radiotherapy. Although remission (absence of detectable lymphoma) can be achieved, the duration of remission usually is short. Recent studies have shown that persons who have NHL/HD but no HIV infection who receive high dose chemotherapy in an effort to destroy any remaining NHL/HD can achieve long-term remission. However, this type of intensive therapy also destroys normal marrow cells. To help reduce this problem, the patient's peripheral blood progenitor cells (PBPC) can be collected part way through chemotherapy to be returned to the subject intravenously (through a vein) after the intensive therapy is over. This procedure is called autologous PBPC transplantation.